GlassScriptPhysician profile
Brock Morris
NPI 1306287024
$1,311.62
in general payments reported to CMS, 2019-2025
14 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $318 · 2023: $288 · 2024: $277 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $401.29 | 2021-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $149.88 | 2023 | |
| Verona Pharma, INC. | $149.16 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $114.92 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $107.21 | 2021-2024 | Prolia, Evenity |
| Alexion Pharmaceuticals, INC. | $84.48 | 2022-2023 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $65.75 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.44 | 2021-2022 | |
| Abbvie INC. | $58.37 | 2021-2024 | |
| Sanofi Pasteur INC. | $36.94 | 2022-2023 | |
| Shield Therapeutics INC | $31.75 | 2024 | |
| Pfizer INC. | $19.01 | 2022 | |
| Merck Sharp & Dohme LLC | $17.55 | 2024 | Gardasil 9, Vaqta, Gardasil |
| Viatris Specialty LLC | $16.87 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brock Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.